Venrock Healthcare Capital Partners II, L.P. 13D and 13G filings for Lyra Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:49 pm Sale | 2024-09-30 | 13G | Lyra Therapeutics, Inc. LYRA | Venrock Healthcare Capital Partners II, L.P. | 1,204,094 1.800% | -4,349,458 (-78.32%) | Filing |
| 2024-02-14 8:35 pm Purchase | 2023-12-31 | 13G | Lyra Therapeutics, Inc. LYRA | Venrock Healthcare Capital Partners II, L.P. | 5,553,552 9.999% | 2,120,284 (+61.76%) | Filing |
| 2023-02-14 4:40 pm Purchase | 2022-12-31 | 13G | Lyra Therapeutics, Inc. LYRA | Venrock Healthcare Capital Partners II, L.P. | 3,433,268 9.999% | 218 (+0.01%) | Filing |
| 2022-04-22 4:05 pm Purchase | 2022-04-12 | 13G | Lyra Therapeutics, Inc. LYRA | Venrock Healthcare Capital Partners II, L.P. | 3,433,050 9.999% | 3,433,050 (New Position) | Filing |